An investigational Alzheimer’s treatment from Biogen and Eisai slowed the rate of cognitive decline by 27% in a clinical trial, meeting the study’s goals.
“Colombia is planting a flag for global health equity,” said Peter Maybarduk, who heads the access to medicines campaign at Public Citizen.
Spending on GLP-1 drugs like Ozempic and Wegovy ballooned last year and they’re set to cost the U.S. health care system and the federal government…
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth’s OptumRx unit will not be renewed after they expire in June.
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Biocon is developing a generic version of Novo Nordisk’s Wegovy and is prepared to conduct a clinical trial next year if needed.
BIO’s about-face in its relationship with WuXi AppTec illustrates the difficulty the biotech industry faces in dealing with an issue that is moving fast and…
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week…
A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.
